e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Treatment of tuberculosis and adverse drug reactions
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Severe adverse effects of antitubercular drugs and patient management
J. Ben Amar, B. Dhari, L. El Gharbi, M. A. Baccar, S. Azzabi, H. Aouina, H. Bouacha (Tunis, Tunisia)
Source:
Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Session:
Treatment of tuberculosis and adverse drug reactions
Session type:
Thematic Poster Session
Number:
4405
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Ben Amar, B. Dhari, L. El Gharbi, M. A. Baccar, S. Azzabi, H. Aouina, H. Bouacha (Tunis, Tunisia). Severe adverse effects of antitubercular drugs and patient management. Eur Respir J 2011; 38: Suppl. 55, 4405
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Adverse effects of anti-tuberculosis drugs in hemodialysis patients
Source: International Congress 2019 – Tuberculosis and comorbidities
Year: 2019
Management of adverse drug events in TB therapy
Source: Eur Respir Mon 2012; 58: 167-193
Year: 2012
Adverse anti-tuberculosis drug events and their management
Source: Eur Respir Monogr 2018; 82: 205-227
Year: 2018
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Adverse effects analysis results during anti-TB treatment among hemodialysis patients
Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis
Year: 2021
Cardiovascular adverse effects during itraconazole therapy
Source: Eur Respir J 2008; 32: 240
Year: 2008
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Can toxicities induced by antituberculosis drugs be better managed in diabetic patients?
Source: Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017
Year: 2017
Experimental justification choise to prevent hepatotoxic reactions to anti-TB drugs based on gene-phenotypic characteristics
Source: International Congress 2019 – Tuberculosis: diagnosis
Year: 2019
Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 650s
Year: 2005
Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease
Source: Eur Respir J 2004; 24: Suppl. 48, 280s
Year: 2004
The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 134s
Year: 2003
The side-effects of TB therapy: myth and reality
Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties
Year: 2005
Noncompliance on antituberculosis treatment and the psychological profile
Source: Eur Respir J 2001; 18: Suppl. 33, 467s
Year: 2001
The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes
Source: Eur Respir J 2004; 24: Suppl. 48, 654s
Year: 2004
Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016
Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Manifestations of hypersensitivity to anti-tuberculosis drugs
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept